Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals

[Display omitted] •The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs to combat COVID-19;•The hydroxamates and thiosemicarbazones effectively inhibited Mpro with an IC50 in range of 0.12–34.22 μM;•The hydroxamates irreversibly, but thiosemicarbazones reversibly and compet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic chemistry 2022-07, Vol.124, p.105799-105799, Article 105799
Hauptverfasser: Xu, Yin-Sui, Chigan, Jia-Zhu, Li, Jia-Qi, Ding, Huan-Huan, Sun, Le-Yun, Liu, Lu, Hu, Zhenxin, Yang, Ke-Wu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 105799
container_issue
container_start_page 105799
container_title Bioorganic chemistry
container_volume 124
creator Xu, Yin-Sui
Chigan, Jia-Zhu
Li, Jia-Qi
Ding, Huan-Huan
Sun, Le-Yun
Liu, Lu
Hu, Zhenxin
Yang, Ke-Wu
description [Display omitted] •The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs to combat COVID-19;•The hydroxamates and thiosemicarbazones effectively inhibited Mpro with an IC50 in range of 0.12–34.22 μM;•The hydroxamates irreversibly, but thiosemicarbazones reversibly and competitively bind to Mpro. The emerging COVID-19 pandemic generated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has severely threatened human health. The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs, which plays a vital role for viral duplication. Development of the inhibitor against Mpro is an ideal strategy to combat COVID-19. In this work, twenty-three hydroxamates 1a-i and thiosemicarbazones 2a-n were identified by FRET screening to be the potent inhibitors of Mpro, which exhibited more than 94% (except 1c) and more than 69% inhibition, and an IC50 value in the range of 0.12–31.51 and 2.43–34.22 μM, respectively. 1a and 2b were found to be the most effective inhibitors in the hydroxamates and thiosemicarbazones, with an IC50 of 0.12 and 2.43 μM, respectively. Enzyme kinetics, jump dilution and thermal shift assays revealed that 2b is a competitive inhibitor of Mpro, while 1a is a time-dependently inhibitor; 2b reversibly but 1a irreversibly bound to the target; the binding of 2b increased but 1a decreased stability of the target, and DTT assays indicate that 1a is the promiscuous cysteine protease inhibitor. Cytotoxicity assays showed that 1a has low, but 2b has certain cytotoxicity on the mouse fibroblast cells (L929). Docking studies revealed that the benzyloxycarbonyl carbon of 1a formed thioester with Cys145, while the phenolic hydroxyl oxygen of 2b formed H-bonds with Cys145 and Asn142. This work provided two promising scaffolds for the development of Mpro inhibitors to combat COVID-19.
doi_str_mv 10.1016/j.bioorg.2022.105799
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9014651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0045206822002048</els_id><sourcerecordid>2655103529</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-c8e750196205b2ba0db94c58922f3e4e12204e0868a69068e33bd6d7774273ce3</originalsourceid><addsrcrecordid>eNp9UcFuEzEQtRCIhsIfIOQjlw1jr-1dc0CqIqBIlZBo4Wp57dnE0e462JuU8PW4Silw4TTSzLz35s0j5CWDJQOm3myXXYgxrZccOC8t2Wj9iCwYaKg44_CYLACErDio9ow8y3kLwJho1FNyVkuhOK_lgkyXR5_iDzvaGamdPJ03IWYcg7Opsz_jhG_pzW2km7DeDEe6S3EMOUxrmp3t-zj4TPuYCgqpxwMOcTfiNNPY0-uLL9fVKn6reOGdwyEkO-Tn5ElfCr64r-fk64f3N6vL6urzx0-ri6vKCVXPlWuxkcC04iA73lnwnRZOtprzvkaBjHMQCK1qrdLFH9Z155VvmkbwpnZYn5N3J97dvhvRu3JTkTe7FEabjibaYP6dTGFj1vFgNDChJCsEr-8JUvy-xzyb4tvhMNgJ4z4brqRkUEuuy6o4rboUc07YP8gwMHdRma05RWXuojKnqArs1d8nPoB-Z_PHA5ZHHQImk13AyaEPCd1sfAz_V_gFZFCoVw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2655103529</pqid></control><display><type>article</type><title>Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Xu, Yin-Sui ; Chigan, Jia-Zhu ; Li, Jia-Qi ; Ding, Huan-Huan ; Sun, Le-Yun ; Liu, Lu ; Hu, Zhenxin ; Yang, Ke-Wu</creator><creatorcontrib>Xu, Yin-Sui ; Chigan, Jia-Zhu ; Li, Jia-Qi ; Ding, Huan-Huan ; Sun, Le-Yun ; Liu, Lu ; Hu, Zhenxin ; Yang, Ke-Wu</creatorcontrib><description>[Display omitted] •The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs to combat COVID-19;•The hydroxamates and thiosemicarbazones effectively inhibited Mpro with an IC50 in range of 0.12–34.22 μM;•The hydroxamates irreversibly, but thiosemicarbazones reversibly and competitively bind to Mpro. The emerging COVID-19 pandemic generated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has severely threatened human health. The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs, which plays a vital role for viral duplication. Development of the inhibitor against Mpro is an ideal strategy to combat COVID-19. In this work, twenty-three hydroxamates 1a-i and thiosemicarbazones 2a-n were identified by FRET screening to be the potent inhibitors of Mpro, which exhibited more than 94% (except 1c) and more than 69% inhibition, and an IC50 value in the range of 0.12–31.51 and 2.43–34.22 μM, respectively. 1a and 2b were found to be the most effective inhibitors in the hydroxamates and thiosemicarbazones, with an IC50 of 0.12 and 2.43 μM, respectively. Enzyme kinetics, jump dilution and thermal shift assays revealed that 2b is a competitive inhibitor of Mpro, while 1a is a time-dependently inhibitor; 2b reversibly but 1a irreversibly bound to the target; the binding of 2b increased but 1a decreased stability of the target, and DTT assays indicate that 1a is the promiscuous cysteine protease inhibitor. Cytotoxicity assays showed that 1a has low, but 2b has certain cytotoxicity on the mouse fibroblast cells (L929). Docking studies revealed that the benzyloxycarbonyl carbon of 1a formed thioester with Cys145, while the phenolic hydroxyl oxygen of 2b formed H-bonds with Cys145 and Asn142. This work provided two promising scaffolds for the development of Mpro inhibitors to combat COVID-19.</description><identifier>ISSN: 0045-2068</identifier><identifier>ISSN: 1090-2120</identifier><identifier>EISSN: 1090-2120</identifier><identifier>DOI: 10.1016/j.bioorg.2022.105799</identifier><identifier>PMID: 35462235</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antiviral Agents - chemistry ; Coronavirus 3C Proteases ; COVID-19 Drug Treatment ; Humans ; Hydroxamates ; Inhibitor ; Main protease ; Mice ; Molecular Docking Simulation ; Pandemics ; Protease Inhibitors - chemistry ; SARS-CoV-2 ; Thiosemicarbazones ; Thiosemicarbazones - pharmacology</subject><ispartof>Bioorganic chemistry, 2022-07, Vol.124, p.105799-105799, Article 105799</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><rights>2022 Elsevier Inc. All rights reserved. 2022 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-c8e750196205b2ba0db94c58922f3e4e12204e0868a69068e33bd6d7774273ce3</citedby><cites>FETCH-LOGICAL-c463t-c8e750196205b2ba0db94c58922f3e4e12204e0868a69068e33bd6d7774273ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bioorg.2022.105799$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35462235$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yin-Sui</creatorcontrib><creatorcontrib>Chigan, Jia-Zhu</creatorcontrib><creatorcontrib>Li, Jia-Qi</creatorcontrib><creatorcontrib>Ding, Huan-Huan</creatorcontrib><creatorcontrib>Sun, Le-Yun</creatorcontrib><creatorcontrib>Liu, Lu</creatorcontrib><creatorcontrib>Hu, Zhenxin</creatorcontrib><creatorcontrib>Yang, Ke-Wu</creatorcontrib><title>Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals</title><title>Bioorganic chemistry</title><addtitle>Bioorg Chem</addtitle><description>[Display omitted] •The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs to combat COVID-19;•The hydroxamates and thiosemicarbazones effectively inhibited Mpro with an IC50 in range of 0.12–34.22 μM;•The hydroxamates irreversibly, but thiosemicarbazones reversibly and competitively bind to Mpro. The emerging COVID-19 pandemic generated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has severely threatened human health. The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs, which plays a vital role for viral duplication. Development of the inhibitor against Mpro is an ideal strategy to combat COVID-19. In this work, twenty-three hydroxamates 1a-i and thiosemicarbazones 2a-n were identified by FRET screening to be the potent inhibitors of Mpro, which exhibited more than 94% (except 1c) and more than 69% inhibition, and an IC50 value in the range of 0.12–31.51 and 2.43–34.22 μM, respectively. 1a and 2b were found to be the most effective inhibitors in the hydroxamates and thiosemicarbazones, with an IC50 of 0.12 and 2.43 μM, respectively. Enzyme kinetics, jump dilution and thermal shift assays revealed that 2b is a competitive inhibitor of Mpro, while 1a is a time-dependently inhibitor; 2b reversibly but 1a irreversibly bound to the target; the binding of 2b increased but 1a decreased stability of the target, and DTT assays indicate that 1a is the promiscuous cysteine protease inhibitor. Cytotoxicity assays showed that 1a has low, but 2b has certain cytotoxicity on the mouse fibroblast cells (L929). Docking studies revealed that the benzyloxycarbonyl carbon of 1a formed thioester with Cys145, while the phenolic hydroxyl oxygen of 2b formed H-bonds with Cys145 and Asn142. This work provided two promising scaffolds for the development of Mpro inhibitors to combat COVID-19.</description><subject>Animals</subject><subject>Antiviral Agents - chemistry</subject><subject>Coronavirus 3C Proteases</subject><subject>COVID-19 Drug Treatment</subject><subject>Humans</subject><subject>Hydroxamates</subject><subject>Inhibitor</subject><subject>Main protease</subject><subject>Mice</subject><subject>Molecular Docking Simulation</subject><subject>Pandemics</subject><subject>Protease Inhibitors - chemistry</subject><subject>SARS-CoV-2</subject><subject>Thiosemicarbazones</subject><subject>Thiosemicarbazones - pharmacology</subject><issn>0045-2068</issn><issn>1090-2120</issn><issn>1090-2120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UcFuEzEQtRCIhsIfIOQjlw1jr-1dc0CqIqBIlZBo4Wp57dnE0e462JuU8PW4Silw4TTSzLz35s0j5CWDJQOm3myXXYgxrZccOC8t2Wj9iCwYaKg44_CYLACErDio9ow8y3kLwJho1FNyVkuhOK_lgkyXR5_iDzvaGamdPJ03IWYcg7Opsz_jhG_pzW2km7DeDEe6S3EMOUxrmp3t-zj4TPuYCgqpxwMOcTfiNNPY0-uLL9fVKn6reOGdwyEkO-Tn5ElfCr64r-fk64f3N6vL6urzx0-ri6vKCVXPlWuxkcC04iA73lnwnRZOtprzvkaBjHMQCK1qrdLFH9Z155VvmkbwpnZYn5N3J97dvhvRu3JTkTe7FEabjibaYP6dTGFj1vFgNDChJCsEr-8JUvy-xzyb4tvhMNgJ4z4brqRkUEuuy6o4rboUc07YP8gwMHdRma05RWXuojKnqArs1d8nPoB-Z_PHA5ZHHQImk13AyaEPCd1sfAz_V_gFZFCoVw</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Xu, Yin-Sui</creator><creator>Chigan, Jia-Zhu</creator><creator>Li, Jia-Qi</creator><creator>Ding, Huan-Huan</creator><creator>Sun, Le-Yun</creator><creator>Liu, Lu</creator><creator>Hu, Zhenxin</creator><creator>Yang, Ke-Wu</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals</title><author>Xu, Yin-Sui ; Chigan, Jia-Zhu ; Li, Jia-Qi ; Ding, Huan-Huan ; Sun, Le-Yun ; Liu, Lu ; Hu, Zhenxin ; Yang, Ke-Wu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-c8e750196205b2ba0db94c58922f3e4e12204e0868a69068e33bd6d7774273ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antiviral Agents - chemistry</topic><topic>Coronavirus 3C Proteases</topic><topic>COVID-19 Drug Treatment</topic><topic>Humans</topic><topic>Hydroxamates</topic><topic>Inhibitor</topic><topic>Main protease</topic><topic>Mice</topic><topic>Molecular Docking Simulation</topic><topic>Pandemics</topic><topic>Protease Inhibitors - chemistry</topic><topic>SARS-CoV-2</topic><topic>Thiosemicarbazones</topic><topic>Thiosemicarbazones - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yin-Sui</creatorcontrib><creatorcontrib>Chigan, Jia-Zhu</creatorcontrib><creatorcontrib>Li, Jia-Qi</creatorcontrib><creatorcontrib>Ding, Huan-Huan</creatorcontrib><creatorcontrib>Sun, Le-Yun</creatorcontrib><creatorcontrib>Liu, Lu</creatorcontrib><creatorcontrib>Hu, Zhenxin</creatorcontrib><creatorcontrib>Yang, Ke-Wu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bioorganic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Yin-Sui</au><au>Chigan, Jia-Zhu</au><au>Li, Jia-Qi</au><au>Ding, Huan-Huan</au><au>Sun, Le-Yun</au><au>Liu, Lu</au><au>Hu, Zhenxin</au><au>Yang, Ke-Wu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals</atitle><jtitle>Bioorganic chemistry</jtitle><addtitle>Bioorg Chem</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>124</volume><spage>105799</spage><epage>105799</epage><pages>105799-105799</pages><artnum>105799</artnum><issn>0045-2068</issn><issn>1090-2120</issn><eissn>1090-2120</eissn><abstract>[Display omitted] •The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs to combat COVID-19;•The hydroxamates and thiosemicarbazones effectively inhibited Mpro with an IC50 in range of 0.12–34.22 μM;•The hydroxamates irreversibly, but thiosemicarbazones reversibly and competitively bind to Mpro. The emerging COVID-19 pandemic generated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has severely threatened human health. The main protease (Mpro) of SARS-CoV-2 is promising target for antiviral drugs, which plays a vital role for viral duplication. Development of the inhibitor against Mpro is an ideal strategy to combat COVID-19. In this work, twenty-three hydroxamates 1a-i and thiosemicarbazones 2a-n were identified by FRET screening to be the potent inhibitors of Mpro, which exhibited more than 94% (except 1c) and more than 69% inhibition, and an IC50 value in the range of 0.12–31.51 and 2.43–34.22 μM, respectively. 1a and 2b were found to be the most effective inhibitors in the hydroxamates and thiosemicarbazones, with an IC50 of 0.12 and 2.43 μM, respectively. Enzyme kinetics, jump dilution and thermal shift assays revealed that 2b is a competitive inhibitor of Mpro, while 1a is a time-dependently inhibitor; 2b reversibly but 1a irreversibly bound to the target; the binding of 2b increased but 1a decreased stability of the target, and DTT assays indicate that 1a is the promiscuous cysteine protease inhibitor. Cytotoxicity assays showed that 1a has low, but 2b has certain cytotoxicity on the mouse fibroblast cells (L929). Docking studies revealed that the benzyloxycarbonyl carbon of 1a formed thioester with Cys145, while the phenolic hydroxyl oxygen of 2b formed H-bonds with Cys145 and Asn142. This work provided two promising scaffolds for the development of Mpro inhibitors to combat COVID-19.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35462235</pmid><doi>10.1016/j.bioorg.2022.105799</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0045-2068
ispartof Bioorganic chemistry, 2022-07, Vol.124, p.105799-105799, Article 105799
issn 0045-2068
1090-2120
1090-2120
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9014651
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Animals
Antiviral Agents - chemistry
Coronavirus 3C Proteases
COVID-19 Drug Treatment
Humans
Hydroxamates
Inhibitor
Main protease
Mice
Molecular Docking Simulation
Pandemics
Protease Inhibitors - chemistry
SARS-CoV-2
Thiosemicarbazones
Thiosemicarbazones - pharmacology
title Hydroxamate and thiosemicarbazone: Two highly promising scaffolds for the development of SARS-CoV-2 antivirals
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A05%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxamate%20and%20thiosemicarbazone:%20Two%20highly%20promising%20scaffolds%20for%20the%20development%20of%20SARS-CoV-2%20antivirals&rft.jtitle=Bioorganic%20chemistry&rft.au=Xu,%20Yin-Sui&rft.date=2022-07-01&rft.volume=124&rft.spage=105799&rft.epage=105799&rft.pages=105799-105799&rft.artnum=105799&rft.issn=0045-2068&rft.eissn=1090-2120&rft_id=info:doi/10.1016/j.bioorg.2022.105799&rft_dat=%3Cproquest_pubme%3E2655103529%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2655103529&rft_id=info:pmid/35462235&rft_els_id=S0045206822002048&rfr_iscdi=true